Market Overview:
The global osteoporosis drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of osteoporosis, rising geriatric population, and growing awareness about osteoporosis. The antiresorptive drugs segment is expected to dominate the global osteoporosis drugs market during the forecast period owing to their high efficacy in treating osteoporosis. However, the anabolic drugs segment is projected to grow at a higher CAGR during the forecast period due to their ability to improve bone density and reduce fracture risk.
Product Definition:
Osteoporosis drugs are medications used to prevent and treat osteoporosis, a condition in which bones become thin and weak.
Antiresorptive Drugs:
Antiresorptive drugs are the medications that reduce or eliminate bone loss. They work by reducing or eliminating the action of rheumatoid arthritis, osteoporosis, and other diseases that cause bone loss. The market for antiresorptive drugs is expected to grow due to increasing prevalence of these diseases and technological advancements in drug delivery systems.
Anabolic Drugs:
Anabolic drugs are synthetic substances that are used to stimulate the body's natural process of bone growth. Anabolic drugs act on the bones by increasing their ability to absorb and produce minerals such as calcium and phosphate. The most common types of anabolic steroids available today include testosterone, nandrolone, boldenone, corticosteroids (such as prednisolone), ethylestrenol, and methylated estradiols (mestranol).
Application Insights:
The female osteoporosis drugs market is anticipated to reach USD 1.9 billion by 2030. The growing geriatric population, which is at a high risk of developing osteoporosis, will drive the demand for these drugs in this segment. According to the World Health Organization (WHO), an estimated 60 million people aged 65 or above were registered in 2015 globally and it is expected that number will increase by about 77% by 2030 globally.
The male osteoporosis drugs market was valued at USD 636 million in 2017 owing to increasing awareness about bone health among men as well as increased incidence of low bone mass disorders among them due to less exposure to estrogen during puberty and later on throughout their life span compared with females. Moreover, males are more prone than females toward sports-related injuries including stress fractures and hip fractures because of low bone density which requires regular checkups for early detection and treatment leading Osteopore Ltd., a U.K.
Regional Analysis:
North America dominated the global market in 2017. High prevalence of osteoporosis-related fractures, favorable reimbursement scenario, and increasing R&D activities for new drug development are some of the major factors responsible for its largest share. In addition, presence of key players such as Pfizer Inc.; Merck & Co., Inc.; and Johnson & Johnson Ltd. is also expected to drive growth over the forecast period.
Asia Pacific is estimated to be one of the fastest growing regions during the forecast period owing to high unmet clinical needs coupled with rapidly improving healthcare infrastructure in emerging countries such as China and India. Moreover, rising disposable income levels will also contribute toward market growth during this period due to increased availability of insurance coverage which will enable people suffering from osteoporosis conditions get proper treatment at affordable prices thereby boosting demand for therapeutics in this region over next eight years (Ongoing developments pertaining to reimbursement scenario are expected favorably impact regional market).
Growth Factors:
- Increasing incidence of osteoporosis due to changing lifestyle and aging population.
- Growing awareness about the disease and its treatment options among patients and healthcare professionals.
- Availability of novel drugs with better efficacy and safety profiles.
- Rising demand for minimally invasive procedures for diagnosis and treatment of osteoporosis.
- increasing investment in research & development activities by pharmaceutical companies to develop new drugs for the treatment of osteoporosis
Scope Of The Report
Report Attributes
Report Details
Report Title
Osteoporosis Drugs Market Research Report
By Type
Antiresorptive Drugs, Anabolic Drugs
By Application
Female, Male
By Companies
Eli Lilly, Novartis, Pfizer, Amgen, Merck, Novo nordisk, Actavis, Roche
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Osteoporosis Drugs Market Report Segments:
The global Osteoporosis Drugs market is segmented on the basis of:
Types
Antiresorptive Drugs, Anabolic Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Female, Male
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly
- Novartis
- Pfizer
- Amgen
- Merck
- Novo nordisk
- Actavis
- Roche
Highlights of The Osteoporosis Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antiresorptive Drugs
- Anabolic Drugs
- By Application:
- Female
- Male
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Osteoporosis Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Osteoporosis drugs are medications used to treat osteoporosis. These medications work by reducing the amount of bone loss in the body.
Some of the major companies in the osteoporosis drugs market are Eli Lilly, Novartis, Pfizer, Amgen, Merck, Novo nordisk, Actavis, Roche.
The osteoporosis drugs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Osteoporosis Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Osteoporosis Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Osteoporosis Drugs Market - Supply Chain
4.5. Global Osteoporosis Drugs Market Forecast
4.5.1. Osteoporosis Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Osteoporosis Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Osteoporosis Drugs Market Absolute $ Opportunity
5. Global Osteoporosis Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Osteoporosis Drugs Market Size and Volume Forecast by Type
5.3.1. Antiresorptive Drugs
5.3.2. Anabolic Drugs
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Osteoporosis Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Osteoporosis Drugs Market Size and Volume Forecast by Application
6.3.1. Female
6.3.2. Male
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Osteoporosis Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Osteoporosis Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Osteoporosis Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Osteoporosis Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Osteoporosis Drugs Demand Share Forecast, 2019-2026
9. North America Osteoporosis Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Osteoporosis Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Osteoporosis Drugs Market Size and Volume Forecast by Application
9.4.1. Female
9.4.2. Male
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Osteoporosis Drugs Market Size and Volume Forecast by Type
9.7.1. Antiresorptive Drugs
9.7.2. Anabolic Drugs
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Osteoporosis Drugs Demand Share Forecast, 2019-2026
10. Latin America Osteoporosis Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Osteoporosis Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Osteoporosis Drugs Market Size and Volume Forecast by Application
10.4.1. Female
10.4.2. Male
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Osteoporosis Drugs Market Size and Volume Forecast by Type
10.7.1. Antiresorptive Drugs
10.7.2. Anabolic Drugs
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Osteoporosis Drugs Demand Share Forecast, 2019-2026
11. Europe Osteoporosis Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Osteoporosis Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Osteoporosis Drugs Market Size and Volume Forecast by Application
11.4.1. Female
11.4.2. Male
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Osteoporosis Drugs Market Size and Volume Forecast by Type
11.7.1. Antiresorptive Drugs
11.7.2. Anabolic Drugs
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growt Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Osteoporosis Drugs Demand Share, 2019-2026
12. Asia Pacific Osteoporosis Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Osteoporosis Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Osteoporosis Drugs Market Size and Volume Forecast by Application
12.4.1. Female
12.4.2. Male
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Osteoporosis Drugs Market Size and Volume Forecast by Type
12.7.1. Antiresorptive Drugs
12.7.2. Anabolic Drugs
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Osteoporosis Drugs Demand Share, 2019-2026
13. Middle East & Africa Osteoporosis Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Osteoporosis Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Osteoporosis Drugs Market Size and Volume Forecast by Application
13.4.1. Female
13.4.2. Male
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Osteoporosis Drugs Market Size and Volume Forecast by Type
13.7.1. Antiresorptive Drugs
13.7.2. Anabolic Drugs
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Osteoporosis Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Osteoporosis Drugs Market: Market Share Analysis
14.2. Osteoporosis Drugs Distributors and Customers
14.3. Osteoporosis Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Eli Lilly
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Amgen
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Merck
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Novo nordisk
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Actavis
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Roche
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
